Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00232596 · ClinicalTrials.gov registry record · Phase 3
Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy
A Phase 3 study of Seizures, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 306
- Enrollment target
- 20
- Study locations
NCT00232596 is a Phase 3 study of Seizures that has completed, run by GlaxoSmithKline. The registered enrollment target is 306 participants, below the 927-participant average among 39 other Seizures trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT00232596, a Phase 3 study of Seizures, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 306 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase 3 study is being conducted to evaluate the efficacy and safety of retigabine dosed at 1200 mg/day, in three equally divided doses, compared with placebo in patients with epilepsy who are receiving up to three established antiepileptic drugs (AEDs).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Retigabine
Study Locations (20)
Alabama
- University of Alabama -- Department of Neurology/Epilepsy Center - Birmingham
- North Alabama Neuroscience Research Associates - Huntsville
- Neurology Clinic - Northport
California
- UCSD Thornton Hospital - La Jolla
- University of Southern California - Los Angeles
- West Los Angeles VA Healthcare Center - Los Angeles
Florida
- University of Florida -- Shands Jacksonville - Jacksonville
- University of Miami - Miami
- Lovelace Scientific Resources - Sarasota
Colorado
- Delta Waves - Colorado Springs
- University of Colorado Health Science Center - Denver
Arizona
- Barrow Neurological Institute - Phoenix
Arkansas
- Clinical Trials Inc. - Little Rock
Iowa
- McFarland Clinic - Ames
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 306 participants |
| Start Date | 2005-09 |
| Est. Completion | 2008-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00232596
The ClinicalTrials.gov registry entry for NCT00232596 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 306 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 927-participant average among 39 other Seizures trials with a reported enrollment target (67% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Seizures appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00232596 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Alabama, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00232596 about?
NCT00232596 is a clinical study titled "Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy". This Phase 3 study is being conducted to evaluate the efficacy and safety of retigabine dosed at 1200 mg/day, in three equally divided doses, compared with placebo in patients with epilepsy who are receiving up to three established antiepileptic drugs (AEDs).
What is the current status of trial NCT00232596?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 306 participants. The study started on 2005-09. Estimated completion is 2008-01.
What conditions does trial NCT00232596 study?
This clinical trial studies the following conditions: Seizures.
What interventions are being tested in trial NCT00232596?
The interventions under investigation include: Placebo (DRUG), Retigabine (DRUG).
Who is sponsoring clinical trial NCT00232596?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00232596 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seizures
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pediatric Dose Optimization for Seizures in Emergency Medical Services
RECRUITING · Phase 3
-
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
RECRUITING · Phase 3
-
Clobazam in Patients With Lennox-Gastaut Syndrome
COMPLETED · Phase 3
-
Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study
COMPLETED · Phase 3
-
Does Gabapentin and Lamotriginel Have Significantly Fewer Side-effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly.
COMPLETED · Phase 3
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.